Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Nasal Polyposis - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 06 Sep 17

The "Nasal Polyposis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Nasal Polyposis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasal Polyposis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 1 and 3 respectively.

Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Nasal Polyposis - Overview
  3. Nasal Polyposis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Nasal Polyposis - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Nasal Polyposis - Companies Involved in Therapeutics Development
  • Cumberland Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • OptiNose US Inc
  • Regeneron Pharmaceuticals Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.